Document is current
Any future updates will be listed below
-
Authors
Bao, Xiuqin
Gao, Yuanyi
Chen, Xiaoyi
Wang, Zhongju
Feng, Xiaoqin
Wang, Liren
Du, Jing
Ye, Yuhua
Chen, Feijing
Du, Li
Yin, Aihua
Xu, Xiangmin
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (U20A20353, 82100136)
“Guangdong Special Support Plan” Provincial Health and Health Commission (Health Talent) Project (0720240246)
the Basic and Applied Basic Research Foundation of GuangDong Province (2023A1515010254)
Guangzhou Municipal Science and Technology Project (2025A03J4205)
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 25 February 2025
First Online: 28 March 2025
Change Date: 11 April 2025
Change Type: Update
Change Details: The original online version of this article was revised: The missing author contribution added.
Declarations
:
: The healthy donors and patients with β-thalassemia were enrolled in Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Informed consents were obtained and the performants were complying with relevant ethnic regulations. β-thalassemia patient CD34+ HSPCs were isolated from plerixafor mobilized peripheral blood following Guangdong Women and Children Hospital institutional review board approval and patient informed consent. All animal experiments were approved by the Guangdong Women and Children Hospital Institutional Animal Care and Use Committee.
: The authors declare no competing interests.
